Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy

Basic Research in Cardiology

Volumn 103, Issue 4, 2008, Pages 319-327

  van Linthout, Sophie ^a   Seeland, Ute ^b   Riad, Alexander ^a   Eckhardt, Oleg ^a   Hohl, Mathias ^b   Dhayat, Nasser ^a   Richter, Utz ^a   Fischer, Jens W ^c   Böhm, Michael ^b   Pauschinger, Matthias ^a   Schultheiss, Heinz Peter ^a   Tschöpe, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Diabetes mellitus; Fibrosis; LV dysfunction; MMP 2; MT1 MMP

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; GELATINASE A; INTERSTITIAL COLLAGENASE; MESSENGER RNA; SMAD7 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEART FUNCTION; HEART MUSCLE FIBROSIS; IMMUNOHISTOLOGY; MALE; NONHUMAN; PATHOGENESIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; SYSTOLE; TRANSCRIPTION REGULATION; ZYMOGRAPHY;

ANIMALS; CARDIOMYOPATHIES; COLLAGEN; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; FIBROSIS; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SMAD7 PROTEIN; STREPTOZOCIN; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFORMING GROWTH FACTOR BETA;

EID: 46149083476     PISSN: 03008428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00395-008-0715-2     Document Type: Article

References (45)

1. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR (2006) Matrix metalloproteinases/tissue inhibitors of metalloproteinases: Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113:2089-2096
2. Aimes RT, Quigley JP (1995) Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 270:5872-5876
3. Akula A, Kota MK, Gopisetty SG, Chitrapu RV, Kalagara M, Kalagara S, Veeravalli KK, Gomedhikam JP (2003) Biochemical, histological and echocardiographic changes during experimental cardiomyopathy in STZ-induced diabetic rats. Pharmacol Res 48:429-435
4. Asbun J, Manso AM, Villarreal FJ (2005) Profibrotic influence of high glucose concentration on cardiac fibroblast functions: Effects of losartan and vitamin E. Am J Physiol Heart Circ Physiol 288:H227-H234
5. Bell DS (1995) Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 18:708-714
6. Berman M, Teerlink J, Li L, Mahimkar R, Zhu BQ, Nguyen A, Dahi S, Karliner J, Lovett DH (2006) Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 292:H1847-H1860
7. Bidasee KR, Zhang Y, Shao CH, Wang M, Patel KP, Dincer UD, Besch HR Jr. (2004) Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+-ATPase. Diabetes 53:463-473
8. Bollano E, Omerovic E, Svensson H, Waagstein F, Fu M (2006) Cardiac remodeling rather than disturbed myocardial energy metabolism is associated with cardiac dysfunction in diabetic rats. Int J Cardiol [Epub ahead of print]
9. Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, Schade van Westrum S, Crabbe T, Clements J, d'Ortho MP, Murphy G (1998) The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 273:871-880
10. Coker ML, Zellner JL, Crumbley AJ, Spinale FG (1999) Defects in matrix metalloproteinase inhibitory stoichiometry and selective MMP induction in patients with nonischemic or ischemic dilated cardiomyopathy. Ann N Y Acad Sci 878:559-562
11. Dollery CM, McEwan JR, Henney AM (1995) Matrix metalloproteinases and cardiovascular disease. Circ Res 77:863-868
12. Han SY, Jee YH, Han KH, Kang YS, Kim HK, Han JY, Kim YS, Cha DR (2006) An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol Dial Transplant 21:2406-2416
13. Hayashi T, Sohmiya K, Ukimura A, Endoh S, Mori T, Shimomura H, Okabe M, Terasaki F, Kitaura Y (2003) Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart. Heart 89:1236-1242
14. Kuzuya M, Asai T, Kanda S, Maeda K, Cheng XW, Iguchi A (2001) Glycation cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice. Diabetologia 44:433-436
15. Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A (2006) Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol 26:1120-1125
16. Lee EO, Kang JL, Chong YH (2005) The amyloid-beta peptide suppresses transforming growth factor-beta1-induced matrix metalloproteinase-2 production via Smad7 expression in human monocytic THP-1 cells. J Biol Chem 280:7845-7853
17. Lupia E, Elliot SJ, Lenz O, Zheng F, Hattori M, Striker GE, Striker LJ (1999) IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: Implications for diabetic nephropathy. Diabetes 48:1638-1644
18. Massague J (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1:169-178
19. Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K, Kinugawa S, Tsutsui H (2006) Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 47:711-717
20. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y (1997) Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 272:2446-2451
21. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, Kuhl U, Schultheiss HP (1999) Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 99:2750-2756
22. Phanish MK, Wahab NA, Colville-Nash P, Hendry BM, Dockrell ME (2006) The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem J 393:601-607
23. Pulaski L, Landstrom M, Heldin CH, Souchelnytskyi S (2001) Phosphorylation of Smad7 at Ser-249 does not interfere with its inhibitory role in transforming growth factor-beta-dependent signaling but affects Smad7-dependent transcriptional activation. J Biol Chem 276:14344-14349
24. Rittie L, Berton A, Monboisse JC, Hornebeck W, Gillery P (1999) Decreased contraction of glycated collagen lattices coincides with impaired matrix metalloproteinase production. Biochem Biophys Res Commun 264:488-492
25. Riva E, Andreoni G, Bianchi R, Latini R, Luvara G, Jeremic G, Traquandi C, Tuccinardi L (1998) Changes in diastolic function and collagen content in normotensive and hypertensive rats with long-term streptozotocin-induced diabetes. Pharmacol Res 37:233-240
26. Rutschow S, Li J, Schultheiss HP, Pauschinger M (2006) Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc Res 69:646-656
27. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370:61-65
28. Schaible TF, Malhotra A, Bauman WA, Scheuer J (1983) Left ventricular function after chronic insulin treatment in diabetic and normal rats. J Mol Cell Cardiol 15:445-458
29. Seeland U, Kouchi I, Zolk O, Itter G, Linz W, Bohm M (2002) Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts. J Mol Cell Cardiol 34:151-163
30. Seeland U, Selejan S, Engelhardt S, Muller P, Lohse MJ, Bohm M (2007) Interstitial remodeling in beta1-adrenergic receptor transgenic mice. Basic Res Cardiol 102:183-193
31. Shehadeh A, Regan TJ (1995) Cardiac consequences of diabetes mellitus. Clin Cardiol 18:301-305
32. Singh R, Song RH, Alavi N, Pegoraro AA, Singh AK, Leehey DJ (2001) High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta1. Exp Nephrol 9:249-257
33. Stanton H, Gavrilovic J, Atkinson SJ, d'Ortho MP, Yamada KM, Zardi L, Murphy G (1998) The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J Cell Sci 111(Pt 18):2789-2798
34. Stilli D, Lagrasta C, Berni R, Bocchi L, Savi M, Delucchi F, Graiani G, Monica M, Maestri R, Baruffi S, Rossi S, Macchi E, Musso E, Quaini F (2007) Preservation of ventricular performance at early stages of diabetic cardiomyopathy involves changes in myocyte size, number and intercellular coupling. Basic Res Cardiol 102:488-499
35. Tack I, Elliot SJ, Potier M, Rivera A, Striker GE, Striker LJ (2002) Autocrine activation of the IGF-I signaling pathway in mesangial cells isolated from diabetic NOD mice. Diabetes 51:182-188
36. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ 3rd, Spinale FG (1998) Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97:1708-1715
37. Tschope C, Spillmann F, Rehfeld U, Koch M, Westermann D, Altmann C, Dendorfer A, Walther T, Bader M, Paul M, Schultheiss HP, Vetter R (2004) Improvement of defective sarcoplasmic reticulum Ca2+ transport in diabetic heart of transgenic rats expressing the human kallikrein-1 gene. Faseb J 18:1967-1969
38. Tschope C, Walther T, Escher F, Spillmann F, Du J, Altmann C, Schimke I, Bader M, Sanchez-Ferrer CF, Schultheiss HP, Noutsias M (2005) Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. Faseb J 19:2057-2059
39. Tschope C, Walther T, Koniger J, Spillmann F, Westermann D, Escher F, Pauschinger M, Pesquero JB, Bader M, Schultheiss HP, Noutsias M (2004) Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. Faseb J 18:828-835
40. Vinik AI, Ziegler D (2007) Diabetic cardiovascular autonomic neuropathy. Circulation 115:387-397
41. Wang B, Hao J, Jones SC, Yee MS, Roth JC, Dixon IM (2002) Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am J Physiol Heart Circ Physiol 282:H1685-H1696
42. Wang B, Omar A, Angelovska T, Drobic V, Rattan SG, Jones SC, Dixon IM (2007) Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts. Am J Physiol Heart Circ Physiol 293:H1282-H1290
43. Westermann D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschope C (2007) Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: The role of angiotensin type 1 receptor antagonism. Diabetes 56:641-646
44. Westermann D, Van Linthout S, Dhayat S, Dhayat N, Schmidt A, Noutsias M, Song XY, Spillmann F, Riad A, Schultheiss HP, Tschope C (2007) Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 102:500-507
45. Wrana JL (2000) Regulation of Smad activity. Cell 100:189-192